NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Catalyst Pharmaceuticals, Inc. CPRX
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$589.0M
▲ 19.8% vs FY2024
EPS · FY25
$1.68
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
25.5%
Net margin · FY25
36.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 589.0M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
36 cents of every revenue dollar became profit this year.
Per share
USD 1.68
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
25.5%
Return on equity, FY2025
ROE
Operating margin43.8%
Net margin36.4%
Return on assets21.9%
Each USD of equity produced 25 cents of profit this year.
Returned to shareholders
USD 25.3M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 25.3M
Share of profit11.8%
Consecutive raises—
USD 25.3M in buybacks — 12% of the year's profit went back to shareholders.
Growth
+37.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+40.1%
+37.7%
Net income
+37.1%
+23.4%
EPS, diluted
+30.8%
+18.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.12B
Shares outstanding, FY2025
Change, 5 years+18.0%
Change, 10 years+47.9%
The share count grew 18% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.1B
total assets, end of FY2025
Total assetsUSD 1.1B
EquityUSD 954.3M
CashUSD 709.2M
Current ratio6.08×
Equity funds 86% of total assets.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.6
0.5
0.4
0.2
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Operating income $B
0.3
0.2
0.1
0.1
0.1
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
0.3
0.2
0.1
0.1
0.1
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
0.1
0.1
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Net income $B
0.2
0.2
0.1
0.1
0.0
0.1
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
1.68
1.31
0.63
0.75
0.37
0.71
0.30
−0.33
−0.21
−0.22
−0.25
−0.24
−0.27
−0.14
−0.29
−0.22
−0.48
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
25.5
29.4
20.7
32.8
21.0
58.3
46.1
−51.6
−30.6
−38.1
−44.6
−54.8
−67.5
−44.3
−137.8
−61.0
−79.7
−78.6
−25.4
Shares out B
0.12
0.12
0.11
0.11
0.10
0.10
0.10
0.10
0.10
0.08
0.08
0.07
0.05
0.04
0.02
0.02
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed